Roman Fabbricatore

The overall safety profile of melphalan/HDS was comparable among relevant subgroups with an absence of cumulative toxicity in successive treatment cycles.

Findings suggest a need for interventions to promote equitable use for underrepresented groups and promote PRO use in those with higher symptom burden.

Although findings did not show differences in eating restrictions 1 month following gastrectomy, the mobile intervention may help with symptom management.

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Pooled analysis data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials support the regulatory decision.

The tafasitamab-based regimen was previously approved by the FDA in June 2025 for patients with relapsed/refractory follicular lymphoma.

The γ-secretase inhibitor varegacestat conferred an 84% reduction in the risk of progression or death vs placebo among those with desmoid tumors.

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

A total of 18% of patients with non-ACC metastatic salivary gland carcinoma treated with elraglusib and cisplatin achieved a response in a phase 2 study.

Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.

A clinically meaningful and statistically significant pathologic complete response rate advantage was seen with the enfortumab vedotin combination.

The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

The median OS among patients with triple-class–exposed relapsed/refractory multiple myeloma with or without EMD was 12.6 months vs 36.4 months.

The incidence and severity of AEs with eryaspase/chemotherapy was generally consistent with previous reports of chemotherapy alone in advanced PDAC.

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Grade 3 immune-mediated AEs were observed in 11 patients with extensive-stage small cell lung cancer, which included 2 instances of pneumonitis.

An oncologist at the Georgia Cancer Center discussed the evolution of treatment strategies and emerging therapies for patients with EGFR-mutated disease.

A total of 45% of patients with B-cell acute lymphoblastic leukemia experienced cytokine release syndrome while receiving treatment with MK-1045, of which 3% experienced grade 3 events.

Among patients with NPM1-mutated and KMT2A-rearranged disease, respectively, the ORR was 65% and 41% in the phase 1 KOMET-007 trial.

The FDA approved pirtobrutinib as a treatment for patients with CLL/SLL who received prior BTK inhibition based on the phase 3 BRUIN-CLL-321 trial results.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Developers have outlined plans to initiate a randomized phase 2 trial evaluating silevertinib in patients with newly diagnosed glioblastoma.

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.